PDE5A and erectile dysfunction: Another pharmaceutical PDE-5 inhibitor, vardenafil, also marketed to treat erectile dysfunction and pulmonary arterial hypertension, lowered NLRP3, IL-1beta, active caspase-1, and NLR in experimentally induced murine cholestatic hepatitis [145].